LAD191

DRUG3 trials

Sponsors

Almirall S.A., Almirall, S.A.

Conditions

Autoimmune DiseaseHealthy VolunteersHidradenitis SuppurativaModerate-to-severe hidradenitis suppurativa

Phase 1

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

CompletedNCT06488209

Almirall, S.A.Autoimmune Disease, Healthy Volunteers

Start: 2022-07-29End: 2025-04-03Updated: 2025-11-24

Phase 2

A Study of LAD191 in Adults With Hidradenitis Suppurativa

RecruitingNCT07151937

Almirall, S.A.Hidradenitis Suppurativa

Start: 2025-11-05End: 2027-11-25Target: 200Updated: 2026-05-11

A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

RecruitingCTIS2025-521293-34-00

Almirall S.A.Moderate-to-severe hidradenitis suppurativa

Start: 2025-12-09Target: 128Updated: 2026-01-22